首页 > 最新文献

Neurodegenerative disease management最新文献

英文 中文
Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary 淀粉样蛋白相关成像异常(ARIA)及其放射学、生物学和临床特征:通俗易懂的摘要
IF 2.6 Q3 Medicine Pub Date : 2024-06-03 DOI: 10.1080/17582024.2024.2343539
Harald Hampel, Aya Elhage, Min Cho, James AR Nicoll, Alireza Atri
{"title":"Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary","authors":"Harald Hampel, Aya Elhage, Min Cho, James AR Nicoll, Alireza Atri","doi":"10.1080/17582024.2024.2343539","DOIUrl":"https://doi.org/10.1080/17582024.2024.2343539","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141269417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects and mechanisms of computerized cognitive training in Huntington's disease: protocol for a pilot study 亨廷顿症计算机认知训练的效果和机制:试点研究方案
IF 2.6 Q3 Medicine Pub Date : 2024-05-11 DOI: 10.2217/nmt-2023-0001
Katharine Huynh, S. Jamadar, Julie Stout, K. Voigt, A. Lampit, N. Georgiou‐Karistianis
Huntington's disease (HD) causes progressive cognitive decline, with no available treatments. Computerized cognitive training (CCT) has shown efficacy in other populations, but its effects in HD are largely unknown. This pilot study will explore the effects and neural mechanisms of CCT in HD. The intervention group participants will complete 12 weeks of multidomain CCT. Control group participants will receive lifestyle education and access to CCT after the study. The primary outcome is change in processing speed. Secondary outcomes include – change in other cognitive domains, functional brain network connectivity (derived from MRI) and psychosocial function. Feasibility outcomes include rates of recruitment, adherence and retention. This study may provide insights into the effects of CCT in HD and guide future trials. Clinical Trial Registration: ACTRN12622000908730 ( ClinicalTrials.gov )
亨廷顿氏病(Huntington's disease,HD)会导致认知能力逐渐下降,目前尚无治疗方法。计算机化认知训练(CCT)已在其他人群中显示出疗效,但其对亨廷顿氏病的效果在很大程度上还不为人所知。这项试点研究将探索计算机认知训练对 HD 的影响和神经机制。干预组参与者将完成为期 12 周的多领域 CCT 训练。对照组参与者将接受生活方式教育,并在研究结束后参加 CCT。主要结果是处理速度的变化。次要结果包括:其他认知领域的变化、大脑功能网络连接(通过核磁共振成像)和社会心理功能。可行性结果包括招募率、坚持率和保留率。这项研究可帮助人们深入了解 CCT 对 HD 的影响,并为未来的试验提供指导。临床试验注册:ACTRN12622000908730 ( ClinicalTrials.gov )
{"title":"Effects and mechanisms of computerized cognitive training in Huntington's disease: protocol for a pilot study","authors":"Katharine Huynh, S. Jamadar, Julie Stout, K. Voigt, A. Lampit, N. Georgiou‐Karistianis","doi":"10.2217/nmt-2023-0001","DOIUrl":"https://doi.org/10.2217/nmt-2023-0001","url":null,"abstract":"Huntington's disease (HD) causes progressive cognitive decline, with no available treatments. Computerized cognitive training (CCT) has shown efficacy in other populations, but its effects in HD are largely unknown. This pilot study will explore the effects and neural mechanisms of CCT in HD. The intervention group participants will complete 12 weeks of multidomain CCT. Control group participants will receive lifestyle education and access to CCT after the study. The primary outcome is change in processing speed. Secondary outcomes include – change in other cognitive domains, functional brain network connectivity (derived from MRI) and psychosocial function. Feasibility outcomes include rates of recruitment, adherence and retention. This study may provide insights into the effects of CCT in HD and guide future trials. Clinical Trial Registration: ACTRN12622000908730 ( ClinicalTrials.gov )","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140987261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study. 用于治疗神经退行性疾病的药用大麻:一项开放标签、剂量发现、安全性和有效性研究。
IF 2.6 Q3 Medicine Pub Date : 2024-04-19 DOI: 10.2217/nmt-2023-0011
P. K. Panegyres, Kerry L Lind, Cheryl A MacFarlane, Allana L. Gurney
Aim: Currently, there exist no curative treatments for neurodegenerative disorders. Recently, there has been a resurgence of interest in the use of medicinal cannabis to improve neurological conditions. Methods: A 12-month, open label, dose-finding, safety and efficacy study was conducted including 48 subjects with a variety of neurodegenerative disorders. Results: In our participants, we observed a reduction in pain, improved sleep, enhanced well-being and less agitation. Conclusion: Our findings suggest that medicinal cannabis might be useful in patients with neurodegenerative disorders in controlling pain, enhancing sleep, reducing difficult behaviors, controlling unusual and complex symptoms when other treatments have failed - this offers medicinal cannabis a role in palliation.
目的:目前,还没有治疗神经退行性疾病的方法。最近,人们再次对使用药用大麻来改善神经系统疾病产生了兴趣。研究方法对 48 名患有各种神经退行性疾病的受试者进行了为期 12 个月、开放标签、剂量调查、安全性和有效性研究。研究结果在研究对象中,我们观察到疼痛减轻、睡眠改善、幸福感增强、躁动减少。结论我们的研究结果表明,在其他治疗方法无效的情况下,药用大麻可能有助于神经退行性疾病患者控制疼痛、改善睡眠、减少困难行为、控制异常和复杂的症状 - 这为药用大麻提供了姑息治疗的作用。
{"title":"Medicinal cannabis in neurodegenerative disorders: an open label, dose finding, safety and efficacy study.","authors":"P. K. Panegyres, Kerry L Lind, Cheryl A MacFarlane, Allana L. Gurney","doi":"10.2217/nmt-2023-0011","DOIUrl":"https://doi.org/10.2217/nmt-2023-0011","url":null,"abstract":"Aim: Currently, there exist no curative treatments for neurodegenerative disorders. Recently, there has been a resurgence of interest in the use of medicinal cannabis to improve neurological conditions. Methods: A 12-month, open label, dose-finding, safety and efficacy study was conducted including 48 subjects with a variety of neurodegenerative disorders. Results: In our participants, we observed a reduction in pain, improved sleep, enhanced well-being and less agitation. Conclusion: Our findings suggest that medicinal cannabis might be useful in patients with neurodegenerative disorders in controlling pain, enhancing sleep, reducing difficult behaviors, controlling unusual and complex symptoms when other treatments have failed - this offers medicinal cannabis a role in palliation.","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140684386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glycine and clozapine: potential relevance for the treatment of Parkinson's disease. 甘氨酸和氯氮平:治疗帕金森病的潜在相关性。
IF 2.6 Q3 Medicine Pub Date : 2024-04-11 DOI: 10.2217/nmt-2024-0005
Shawn Maddaford, Philippe Huot
{"title":"Glycine and clozapine: potential relevance for the treatment of Parkinson's disease.","authors":"Shawn Maddaford, Philippe Huot","doi":"10.2217/nmt-2024-0005","DOIUrl":"https://doi.org/10.2217/nmt-2024-0005","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140712784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication. 测量多发性硬化症患者的疲劳程度--应使用哪种问卷?通俗易懂的出版物摘要。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-02-01 Epub Date: 2024-03-19 DOI: 10.2217/nmt-2023-0034
Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann

What is this summary about?: This summary explains the findings of a recent study that compared different questionnaires used by doctors to measure levels of fatigue in people with multiple sclerosis (MS). The aim of the study was to find out which questionnaire doctors should use to measure fatigue in people with MS in the future. Fatigue, which can be described as the overwhelming feeling of tiredness or exhaustion, is a very common symptom of MS. For the majority of people with MS, fatigue is one of the worst symptoms of MS, so it is essential that doctors can measure it accurately. Currently, people with MS are asked to complete questionnaires so that their care team can see the effect of fatigue on their day-to-day lives. There are many questionnaires that are used to measure fatigue in people with MS. It would be valuable to come to an agreement, based on evidence from research like this study, on which questionnaire is the most appropriate for measuring fatigue in both research and healthcare settings. This study compared a questionnaire called the PROMIS® Fatigue (MS) 8a, referred to throughout this summary as the PROMIS® MS Fatigue Short Form, with two of the most commonly used questionnaires: the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS). The questionnaires were compared to see which one should be recommended to doctors for measuring fatigue in people with MS.

What are the key takeaways?: It was found that while all three questionnaires were good, the PROMIS® MS Fatigue Short Form questionnaire was better than the other two questionnaires at showing differences in levels of fatigue between people with MS. The PROMIS® MS Fatigue Short Form was also found to be better than the Fatigue Severity Scale (FSS) at showing changes in the person with MS's level of fatigue. The PROMIS® MS Fatigue Short Form questionnaire may help people with MS to better communicate challenges with their fatigue to their doctors.

What was the main conclusion reported by the researchers?: The study suggests that the PROMIS® MS Fatigue Short Form questionnaire is a helpful tool for doctors and people with MS to measure fatigue.

本摘要说明了近期一项研究的结果,该研究比较了医生用于测量多发性硬化症(MS)患者疲劳程度的不同问卷。这项研究的目的是找出医生今后应该使用哪种问卷来测量多发性硬化症患者的疲劳程度。疲劳可以被描述为一种难以承受的疲倦或精疲力竭的感觉,是多发性硬化症的一种非常常见的症状。对于大多数多发性硬化症患者来说,疲劳是多发性硬化症最严重的症状之一,因此医生必须对其进行准确测量。目前,多发性硬化症患者需要填写调查问卷,以便护理团队了解疲劳对其日常生活的影响。用于测量多发性硬化症患者疲劳程度的问卷有很多。根据本研究等研究的证据,就哪种问卷最适合在研究和医疗环境中测量疲劳达成一致是非常有价值的。本研究将 PROMIS® 疲劳(MS)8a(在本摘要中称为 PROMIS® MS 疲劳简表)问卷与两种最常用的问卷:疲劳严重程度量表(FSS)和改良疲劳影响量表(MFIS)进行了比较。对这两种问卷进行了比较,以确定应向医生推荐哪一种问卷来测量多发性硬化症患者的疲劳程度:研究发现,虽然这三种问卷都不错,但在显示多发性硬化症患者疲劳程度差异方面,PROMIS® 多发性硬化症疲劳简表问卷优于其他两种问卷。在显示多发性硬化症患者疲劳程度的变化方面,PROMIS® 多发性硬化症疲劳简表也优于疲劳严重程度量表(FSS)。PROMIS®多发性硬化症疲劳简表问卷可以帮助多发性硬化症患者更好地向医生表达他们在疲劳方面遇到的挑战:研究表明,PROMIS® 多发性硬化症疲劳简表问卷是医生和多发性硬化症患者测量疲劳的有效工具。
{"title":"Measuring fatigue in people with multiple sclerosis - which questionnaire should be used? A Plain Language Summary of Publication.","authors":"Paul Kamudoni, Jeffrey Johns, Karon F Cook, Rana Salem, Sam Salek, Jana Raab, Rod Middleton, Christian Henke, Dagmar Amtmann","doi":"10.2217/nmt-2023-0034","DOIUrl":"10.2217/nmt-2023-0034","url":null,"abstract":"<p><strong>What is this summary about?: </strong>This summary explains the findings of a recent study that compared different questionnaires used by doctors to measure levels of fatigue in people with multiple sclerosis (MS). The aim of the study was to find out which questionnaire doctors should use to measure fatigue in people with MS in the future. Fatigue, which can be described as the overwhelming feeling of tiredness or exhaustion, is a very common symptom of MS. For the majority of people with MS, fatigue is one of the worst symptoms of MS, so it is essential that doctors can measure it accurately. Currently, people with MS are asked to complete questionnaires so that their care team can see the effect of fatigue on their day-to-day lives. There are many questionnaires that are used to measure fatigue in people with MS. It would be valuable to come to an agreement, based on evidence from research like this study, on which questionnaire is the most appropriate for measuring fatigue in both research and healthcare settings. This study compared a questionnaire called the PROMIS<sup>®</sup> Fatigue (MS) 8a, referred to throughout this summary as the PROMIS<sup>®</sup> MS Fatigue Short Form, with two of the most commonly used questionnaires: the Fatigue Severity Scale (FSS) and the Modified Fatigue Impact Scale (MFIS). The questionnaires were compared to see which one should be recommended to doctors for measuring fatigue in people with MS.</p><p><strong>What are the key takeaways?: </strong>It was found that while all three questionnaires were good, the PROMIS<sup>®</sup> MS Fatigue Short Form questionnaire was better than the other two questionnaires at showing differences in levels of fatigue between people with MS. The PROMIS<sup>®</sup> MS Fatigue Short Form was also found to be better than the Fatigue Severity Scale (FSS) at showing changes in the person with MS's level of fatigue. The PROMIS<sup>®</sup> MS Fatigue Short Form questionnaire may help people with MS to better communicate challenges with their fatigue to their doctors.</p><p><strong>What was the main conclusion reported by the researchers?: </strong>The study suggests that the PROMIS<sup>®</sup> MS Fatigue Short Form questionnaire is a helpful tool for doctors and people with MS to measure fatigue.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11244694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140158616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Welcome to Volume 14 of Neurodegenerative Disease Management. 欢迎阅读《神经退行性疾病管理》第 14 卷。
IF 2.6 Q3 Medicine Pub Date : 2024-02-01 Epub Date: 2024-02-29 DOI: 10.2217/nmt-2023-0045
Afra Paleel
{"title":"Welcome to Volume 14 of <i>Neurodegenerative Disease Management</i>.","authors":"Afra Paleel","doi":"10.2217/nmt-2023-0045","DOIUrl":"10.2217/nmt-2023-0045","url":null,"abstract":"","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139990705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures. 纳比昔莫司治疗多发性硬化症相关痉挛的患者报告获益超过了传统衡量标准。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-02-01 Epub Date: 2024-02-06 DOI: 10.2217/nmt-2023-0040
Michael R Haupts, Ute Essner, Mathias Mäurer

Aim: This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex®) in the real-world setting in Germany. Patients & methods: The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity. Results: The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p < 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0-10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks. Conclusion: Nabiximols is a useful therapeutic option for patients with MS spasticity.

目的:这项为期 12 周的前瞻性、多中心、开放标签、非干预性研究调查了在德国实际环境中添加纳比昔莫司口腔喷雾剂(Sativex®)的有效性和耐受性。患者和方法:主要分析组包括 51 名患有多发性硬化症(MS)痉挛的成年患者(49 名 nabiximols 反应者)。结果从基线到第 12 周,平均总体目标实现量表评分(主要结果测量)增加了 46%(35.2 vs 51.4;P 结论:纳比西莫司是一种有效的治疗药物:纳比昔莫司对多发性硬化痉挛患者是一种有用的治疗选择。
{"title":"Patient-reported benefits from nabiximols treatment in multiple sclerosis-related spasticity exceed conventional measures.","authors":"Michael R Haupts, Ute Essner, Mathias Mäurer","doi":"10.2217/nmt-2023-0040","DOIUrl":"10.2217/nmt-2023-0040","url":null,"abstract":"<p><p><b>Aim:</b> This prospective, multicenter, open-label, noninterventional 12-week study investigated the effectiveness and tolerability of add-on nabiximols oromucosal spray (Sativex<sup>®</sup>) in the real-world setting in Germany. <b>Patients & methods:</b> The main analysis set comprised 51 adult patients (49 nabiximols responders) with multiple sclerosis (MS) spasticity. <b>Results:</b> The mean overall goal attainment scale score (primary outcome measure) increased by 46% from baseline to week 12 (35.2 vs 51.4; p < 0.001). Mean gait speed was improved by 23% at 4 and 12 weeks. Clinically meaningful improvements in mean 0-10 numerical rating scale scores for spasticity, pain, sleep quality and urinary bladder dysfunction were recorded at 4 and 12 weeks. <b>Conclusion:</b> Nabiximols is a useful therapeutic option for patients with MS spasticity.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139692466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Benefits of self-paced concurrent training on lung function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis. 自定进度的同步训练对多发性硬化症患者肺功能、心肺功能和疲劳感的益处。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-10-22 DOI: 10.1080/17582024.2024.2404385
Sonda Jallouli, Rami Maaloul, Sameh Ghroubi, Rim Kammoun, Mariem Damak, Salma Sakka, Tarak Driss, Giovanni de Marco, Chokri Mhiri, Mohamed Habib Elleuch, Walid Feki, Omar Hammouda

Aim: Studying the effects of self-paced concurrent high-intensity interval training and resistance training (HIIT-RT) on respiratory function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis (PwMS).Methods: Twenty-three PwMS were randomized into a 12-week training group (three times per week) (TG, n = 11) or a control group (CG, n = 12). Lung function (spirometry), aerobic capacity (graded cardiopulmonary-exercise-testing) and perceived fatigue (Fatigue Severity Scale (FSS)) were evaluated pre- and post-intervention.Results: The forced vital capacity (p = 0.036, Hedges'g (g) = 0.93), forced expiratory time (p = 0.045, g = 0.88), peak expiratory flow (p = 0.043, g = 0.89) increased in TG compared with CG. The TG showed an increase in peak aerobic power (p = 0.004, g = 1.34) and peak oxygen uptake (p < 0.001, g = 2.58) compared with CG. There was a decrease in ventilatory equivalent for carbon dioxide (p = 0.02, g = 1.02) and FSS scores (p < 0.001, g = 1.72) in TG comparatively with CG.Conclusion: 12-week self-paced HIIT-RT enhanced lung function as well as aerobic fitness, and alleviated fatigue perception in PwMS.

目的:研究自定步骤同时进行的高强度间歇训练和阻力训练(HIIT-RT)对多发性硬化症患者(PwMS)呼吸功能、心肺功能和疲劳感的影响:23 名多发性硬化症患者被随机分为为期 12 周的训练组(每周三次)(TG,n = 11)或对照组(CG,n = 12)。对干预前后的肺功能(肺活量测定)、有氧运动能力(分级心肺运动测试)和疲劳感(疲劳严重程度量表(FSS))进行评估:结果:与 CG 相比,TG 的用力肺活量(p = 0.036,Hedges'g (g) = 0.93)、用力呼气时间(p = 0.045,g = 0.88)和呼气流量峰值(p = 0.043,g = 0.89)均有所增加。TG 的峰值有氧功率(p = 0.004,g = 1.34)、峰值摄氧量(p p = 0.02,g = 1.02)和 FSS 评分(p 结论:为期 12 周的自定步调 HIIT-RT 可增强 PwMS 的肺功能和有氧体能,并缓解疲劳感。
{"title":"Benefits of self-paced concurrent training on lung function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis.","authors":"Sonda Jallouli, Rami Maaloul, Sameh Ghroubi, Rim Kammoun, Mariem Damak, Salma Sakka, Tarak Driss, Giovanni de Marco, Chokri Mhiri, Mohamed Habib Elleuch, Walid Feki, Omar Hammouda","doi":"10.1080/17582024.2024.2404385","DOIUrl":"10.1080/17582024.2024.2404385","url":null,"abstract":"<p><p><b>Aim:</b> Studying the effects of self-paced concurrent high-intensity interval training and resistance training (HIIT-RT) on respiratory function, cardiopulmonary fitness and fatigue perception in patients with multiple sclerosis (PwMS).<b>Methods:</b> Twenty-three PwMS were randomized into a 12-week training group (three times per week) (TG, n = 11) or a control group (CG, n = 12). Lung function (spirometry), aerobic capacity (graded cardiopulmonary-exercise-testing) and perceived fatigue (Fatigue Severity Scale (FSS)) were evaluated pre- and post-intervention.<b>Results:</b> The forced vital capacity (<i>p</i> = 0.036, Hedges'g (g) = 0.93), forced expiratory time (<i>p</i> = 0.045, g = 0.88), peak expiratory flow (<i>p</i> = 0.043, g = 0.89) increased in TG compared with CG. The TG showed an increase in peak aerobic power (<i>p</i> = 0.004, g = 1.34) and peak oxygen uptake (<i>p</i> < 0.001, g = 2.58) compared with CG. There was a decrease in ventilatory equivalent for carbon dioxide (<i>p</i> = 0.02, g = 1.02) and FSS scores (<i>p</i> < 0.001, g = 1.72) in TG comparatively with CG.<b>Conclusion:</b> 12-week self-paced HIIT-RT enhanced lung function as well as aerobic fitness, and alleviated fatigue perception in PwMS.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142504779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options. 难治性抗 NMDAR 脑炎合并多种鼻腔感染:优化治疗方案。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI: 10.1080/17582024.2024.2388508
Sachin G Nair, Elezabeth Koshy, Rajender Kandikonda, Sudheeran Kannoth

Nosocomial infections during immunotherapy pose a dilemma in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, where a lack of consensus guidelines for this rare disease marks a significant gap in the existing knowledge. This case reports about an 18-year-old female diagnosed with anti-NMDAR encephalitis who was found to be refractory to first- and second-line treatment. During her hospital stay, the patient encountered nearly six episodes of infection, which delayed the use of next-line intervention. It was observed that switching over to the next line of treatment during infections may produce sub-therapeutic outcomes. Thereby, the case highlights the need for de-escalation and appropriate selection of immunosuppression therapy during nosocomial infections and how monotherapy with the patient-tolerated first-line agent can be appropriate during infection.

在治疗抗 N-甲基-D-天冬氨酸受体(NMDAR)脑炎的过程中,免疫治疗期间的非病原性感染是一个难题,对于这种罕见疾病缺乏共识性指南标志着现有知识的重大空白。本病例报告了一名被诊断患有抗 NMDAR 脑炎的 18 岁女性患者,她对一线和二线治疗均无效。在住院期间,该患者经历了近六次感染发作,延误了下一步治疗。据观察,在感染期间切换到下一治疗线可能会产生亚治疗效果。因此,该病例突出说明了在发生院内感染时,需要降级和适当选择免疫抑制疗法,以及在感染期间如何适当使用患者可耐受的一线药物进行单药治疗。
{"title":"Refractory anti-NMDAR encephalitis with multiple nosocomial infections: optimizing the therapeutical options.","authors":"Sachin G Nair, Elezabeth Koshy, Rajender Kandikonda, Sudheeran Kannoth","doi":"10.1080/17582024.2024.2388508","DOIUrl":"10.1080/17582024.2024.2388508","url":null,"abstract":"<p><p>Nosocomial infections during immunotherapy pose a dilemma in the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, where a lack of consensus guidelines for this rare disease marks a significant gap in the existing knowledge. This case reports about an 18-year-old female diagnosed with anti-NMDAR encephalitis who was found to be refractory to first- and second-line treatment. During her hospital stay, the patient encountered nearly six episodes of infection, which delayed the use of next-line intervention. It was observed that switching over to the next line of treatment during infections may produce sub-therapeutic outcomes. Thereby, the case highlights the need for de-escalation and appropriate selection of immunosuppression therapy during nosocomial infections and how monotherapy with the patient-tolerated first-line agent can be appropriate during infection.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple system atrophy mimics CASPR2 antibody-associated disease: a case report. 模仿 CASPR2 抗体相关疾病的多系统萎缩:一份病例报告。
IF 2.3 Q3 CLINICAL NEUROLOGY Pub Date : 2024-01-01 Epub Date: 2024-09-25 DOI: 10.1080/17582024.2024.2388506
Xiaoli Chen, Li Feng, Jing Li, Hong Jiang

Aim: Multiple system atrophy (MSA) and CASPR2 antibody-associated disease bear their own characteristics.Case presentation: A 58-year-old woman presented with a 26 months history of uncoordinated gait and slurred speech. Her serum was positive for anti-CASPR2 antibodies, and MRI revealed atrophy of the brainstem and cerebellum. She underwent three plasma exchanges (PE) and received high doses of corticosteroids without any apparent effect. Her autonomic dysfunction improved after repetitive transcranial magnetic stimulation. Eventually, a diagnosis of MSA-cerebellar phenotype(MSA-C) was made.Conclusion: With increased availability of tools for neuron antibody detection, physicians need to be aware of the possibility that antibodies may accompany other diseases. This report underscores the modern dilemmas caused by available and extensive neuron antibody testing.

目的:多系统萎缩(MSA)和 CASPR2 抗体相关疾病各有特点:一名 58 岁的妇女因步态不协调和言语不清就诊 26 个月。她的血清中抗 CASPR2 抗体呈阳性,核磁共振成像显示脑干和小脑萎缩。她进行了三次血浆置换(PE),并接受了大剂量皮质类固醇治疗,但效果不明显。重复经颅磁刺激后,她的自主神经功能障碍有所改善。最终,她被诊断为MSA-小脑表型(MSA-C):结论:随着神经元抗体检测工具的增多,医生需要意识到抗体可能会伴随其他疾病。本报告强调了神经元抗体检测的可用性和广泛性所带来的现代困境。
{"title":"Multiple system atrophy mimics CASPR2 antibody-associated disease: a case report.","authors":"Xiaoli Chen, Li Feng, Jing Li, Hong Jiang","doi":"10.1080/17582024.2024.2388506","DOIUrl":"10.1080/17582024.2024.2388506","url":null,"abstract":"<p><p><b>Aim:</b> Multiple system atrophy (MSA) and CASPR2 antibody-associated disease bear their own characteristics.<b>Case presentation:</b> A 58-year-old woman presented with a 26 months history of uncoordinated gait and slurred speech. Her serum was positive for anti-CASPR2 antibodies, and MRI revealed atrophy of the brainstem and cerebellum. She underwent three plasma exchanges (PE) and received high doses of corticosteroids without any apparent effect. Her autonomic dysfunction improved after repetitive transcranial magnetic stimulation. Eventually, a diagnosis of MSA-cerebellar phenotype(MSA-C) was made.<b>Conclusion:</b> With increased availability of tools for neuron antibody detection, physicians need to be aware of the possibility that antibodies may accompany other diseases. This report underscores the modern dilemmas caused by available and extensive neuron antibody testing.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142350681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurodegenerative disease management
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1